Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-083255
Filing Date
2025-06-06
Accepted
2025-06-06 17:20:05
Documents
2
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2827
2 EX-24 crsp-ex24.htm EX-24 16695
  Complete submission text file 0000950170-25-083255.txt   20948
Mailing Address C/O SYNDAX PHARMACEUTICALS, INC. 400 TOTTEN POND ROAD, SUITE 110 WALTHAM MA 02451
Business Address
Morrison Briggs (Reporting) CIK: 0001654430 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37923 | Film No.: 251032073

Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Issuer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)